Contemporary nano-architectured drugs and leads for ανβ3 integrin-based chemotherapy: Rationale and retrospect

Abbas Nahid; Yusuf Mohammad; Akhtar Naseem; Khan Riaz A.

doi:10.1515/ntrev-2022-0020

Nanotechnology Reviews (Dec 2021)

Contemporary nano-architectured drugs and leads for ανβ3 integrin-based chemotherapy: Rationale and retrospect

Abbas Nahid,
Yusuf Mohammad,
Akhtar Naseem,
Khan Riaz A.

Affiliations

Abbas Nahid: Acharya and BM Reddy College of Pharmacy, Bengaluru, 560 107, India
Yusuf Mohammad: Department of Clinical Pharmacy, Taif University, Taif Al-Haweiah, Taif 21974, Saudi Arabia
Akhtar Naseem: Department of Pharmaceutics, College of Dentistry and Pharmacy, Buraydah Private Colleges, Buraydah, Qassim 51418, Saudi Arabia
Khan Riaz A.: Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia

DOI: https://doi.org/10.1515/ntrev-2022-0020
Journal volume & issue: Vol. 11, no. 1
pp. 204 – 219

Abstract

Read online

The ανβ3 integrin antagonistic ligands, i.e., drugs as nano-architectural design-based nanomedicine, especially for cancer chemotherapy, are discussed.

Published in Nanotechnology Reviews

ISSN: 2191-9089 (Print); 2191-9097 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Technology: Chemical technology; Science: Chemistry: Physical and theoretical chemistry
Website: https://www.degruyter.com/view/j/ntrev

About the journal

Abstract

Keywords